MaxCyte, Inc. - Trading Update
· First-half revenues at
· Launch of expanded new ExPERT™ range of disposables to broaden applications by customers
· CARMA preliminary clinical data due in H2 2020
· Management to host conference call today at
Strong current trading and continuing momentum
First half revenues are expected to increase approximately 30% year-on-year to
Successful financing raised in the period
The Company closed a successful
Robust growth in cell therapy business
During the first half of the year and into July,
Update on CARMA Cell Therapies™
In addition, clinical data from the first three cohorts of the ongoing Phase I dose-escalation trial demonstrating safety of CARMA Cell Therapies' clinical candidate MCY-M11, and feasibility of one-day manufacturing, were shared at the
Launch of new ExPERT™ range of expanded research and GMP grade disposables for complex cellular engineering
"We remain mindful of the impact of the COVID-19 global pandemic and continue to work diligently to mitigate any potential restrictions and delays in our operations and to protect our team, their families, our customers and patients. We remain confident in our prospects for long-term growth fuelled by our next-generation gene-editing enabling technology and a resilient business model. We look forward to providing a more detailed update with our half-year results in September."
Conference call today
A conference call with Q&A for analysts hosted by CEO
Participant dial-in (
Participant dial-in (US): 1 877 870 9135
International dial-in: +44 (0) 2071 928338
Conference ID: 9674639
A replay facility will be made available on the MaxCyte Website.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.
For further information, please contact:
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identiﬁed by their use of terms and phrases such as ''believe'', ''could'', "should", "expect", ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reﬂect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.
A number of factors could cause actual results to differ materially from the results and expectations discussed in the forward-looking statements, many of which are beyond the control of the Company. In particular, the outcome of clinical trials (including, but not limited to the Company's CARMA trial) may not be favourable or potential milestone payments associated with the Company's licensed programmes may not be received. In addition, other factors which could cause actual results to differ materially include risks associated with vulnerability to general economic and business conditions, competition, regulatory changes, actions by governmental authorities, the availability of capital markets, reliance on key personnel, uninsured and underinsured losses and other factors. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward looking statements. Accordingly, readers are cautioned not to place undue reliance on forward looking statements. Subject to any continuing obligations under applicable law or any relevant AIM Rule requirements, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based.
This information is provided by RNS, the news service of the
Quick facts: MaxCyte Inc
Market Cap: -
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE